Jyong Biotech (MENS) AGM 2026 summary

Strategic initiatives and plans

• MCS-2 product offers a unique mechanism of action for benign prostatic hyperplasia, addressing unmet patient needs with a strong safety profile.

• Positioned among the first five companies to receive FDA phase III clinical trial approval for a botanical drug, with potential for early market entry.

Key challenges and risks discussed

• Emphasis on the lack of effective current treatments for benign prostatic hyperplasia highlights the market need and potential hurdles in patient care.